This would enable more precise optimization of the GAD-7 and GAD-2 cut-points for use among young adults perinatally affected by HIV, thereby ensuring effective anxiety screening in this population and prevention of increasing psychiatric disorders and impairment. The gene discussed is GAD1; the disease is psychiatric disorder.